Compare UFCS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFCS | MLYS |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.5B |
| IPO Year | 1995 | 2023 |
| Metric | UFCS | MLYS |
|---|---|---|
| Price | $54.08 | $28.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $40.50 | ★ $48.67 |
| AVG Volume (30 Days) | 113.9K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | 37.43 |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $1,386,412,000.00 | N/A |
| Revenue This Year | $11.80 | N/A |
| Revenue Next Year | $8.77 | N/A |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $29.75 | $22.30 |
| 52 Week High | $56.74 | $47.65 |
| Indicator | UFCS | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 52.21 |
| Support Level | $52.21 | $25.56 |
| Resistance Level | $55.12 | $31.36 |
| Average True Range (ATR) | 1.38 | 1.58 |
| MACD | -0.09 | 0.11 |
| Stochastic Oscillator | 41.44 | 45.15 |
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.